Minneapolis, USA, and Brisbane, Australia – November 3, 2025
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has announced U.S. Food and Drug Administration (FDA) approval to initiate its global pivotal PARADIGM trial, a randomized controlled study evaluating the DurAVR® Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis. The PARADIGM (Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices) will serve as the key study to support a future Premarket Approval (PMA) submission to the FDA, marking a critical milestone for Anteris and for the next generation of biomimetic structural heart technologies.
Science Significance
The DurAVR® Transcatheter Heart Valve represents a technological leap in cardiovascular innovation, being the first biomimetic valve designed to replicate the natural shape and function of a healthy human aortic valve. Built from ADAPT® tissue, Anteris’ patented anti-calcification technology, the valve provides physiologic blood flow that mimics natural aortic dynamics, potentially reducing complications and improving durability. The trial’s randomized head-to-head design against commercially available TAVR devices will generate Level 1 clinical evidence, the highest standard for establishing medical device safety and efficacy. This study reinforces Anteris’s scientific leadership in tissue engineering and hemodynamic design, setting a new standard for evidence-based innovation in the treatment of aortic stenosis.
Regulatory Significance
The FDA’s approval of the Investigational Device Exemption (IDE) application for PARADIGM reflects regulatory confidence in Anteris’s preclinical data and device safety profile. The pivotal study, enrolling approximately 1,000 patients across the U.S., Europe, and Canada, is structured to demonstrate non-inferiority in all-cause mortality, stroke, and cardiovascular hospitalization one year post-procedure. The trial’s results will form the cornerstone of Anteris’s Premarket Approval (PMA) submission in the U.S., while CE Mark approval will be pursued in parallel. This global dual-path regulatory strategy illustrates how Anteris is aligning with FDA and international device standards, ensuring cGxP compliance and harmonized approval for faster patient access to life-saving technology.
Advertisement
Business Significance
FDA approval for the PARADIGM trial is a strategic milestone that significantly enhances Anteris’s commercial and investor position. With this clearance, the company transitions from a development-stage innovator to a clinical-stage global player in the structural heart device market, an industry projected to surpass $15 billion by 2030. The DurAVR® THV’s proprietary design and tissue technology differentiate it from current TAVR systems, potentially expanding Anteris’s market share and competitive advantage in both transcatheter and surgical heart valve segments. The collaboration with top global cardiology leaders, including Dr. Michael Reardon (Houston Methodist Hospital) and Prof. Stephan Windecker (Bern University Hospital), underscores the scientific and clinical credibility backing this pivotal trial and its path toward commercialization.
Patients’ Significance
For patients suffering from severe calcific aortic stenosis, one of the most common and life-threatening heart valve diseases, the DurAVR® THV offers renewed hope. Current TAVR devices, though effective, can result in non-physiologic flow dynamics, leading to valve deterioration over time. The DurAVR® THV’s biomimetic structure is engineered to restore natural valve motion and smoother blood flow, which could enhance long-term outcomes and quality of life. With over 55,000 ADAPT® tissue-based devices already implanted worldwide, the clinical confidence in this technology is growing rapidly. The PARADIGM trial aims to validate that next-generation biomimetic valves can deliver superior hemodynamics and durability, fundamentally improving patient survival and post-procedure recovery.
Policy Significance
The initiation of the PARADIGM trial reflects a successful partnership between innovation and regulatory science, aligning with FDA’s mission to advance safe, effective, and high-quality medical technologies. It demonstrates how data-driven clinical design and global collaboration can accelerate device approvals while maintaining the integrity of cGxP frameworks. Moreover, by pursuing simultaneous U.S. and European regulatory pathways, Anteris exemplifies an international model for harmonized medical device approval, supporting broader policy goals around global patient access to breakthrough cardiovascular therapies. This approach strengthens confidence among regulators, clinicians, and investors that innovation can proceed responsibly within robust compliance systems.
The FDA’s approval of Anteris’s PARADIGM global pivotal trial marks a historic advance in the field of structural heart medicine. By combining biomimetic engineering, regulatory excellence, and clinical collaboration, Anteris Technologies is paving the way for a new generation of life-saving heart valve therapies. As the PARADIGM study begins patient enrollment across North America and Europe, it represents not just a corporate milestone but a transformative step for cardiovascular science, bringing the promise of natural valve restoration and long-term cardiac health one step closer to reality.
Source: Anteris Technologies Pty Ltd press release
